An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes

M. Reni, H. Riess, E. O'Reilly, A. Santoro, J. Park, T. Bekaii-Saab, M. Tempero, Y. Shan, T. Macarulla, E. Van Cutsem, M. Noel, J. Berlin, A. Biankin, N. Dhani, G. Frassineti, D. Goldstein, A. Romano, Y. Le Bruchec, P. Philip

研究成果: Article

原文English
頁(從 - 到)iv126
期刊Annals of Oncology
30
DOIs
出版狀態Published - 2019 七月

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

引用此

Reni, M., Riess, H., O'Reilly, E., Santoro, A., Park, J., Bekaii-Saab, T., Tempero, M., Shan, Y., Macarulla, T., Van Cutsem, E., Noel, M., Berlin, J., Biankin, A., Dhani, N., Frassineti, G., Goldstein, D., Romano, A., Bruchec, Y. L., & Philip, P. (2019). An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes. Annals of Oncology, 30, iv126. https://doi.org/10.1093/annonc/mdz154